Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a group of FDA-approved drugs used to treat low blood sugar in adults suffering from Type-2 diabetes. However, in 2015, the FDA issued a warning that Invokana and other SGLT2 inhibitors can trigger a condition known as diabetic ketoacidosis (DKA). This condition is caused by very high levels of acid in blood. In addition, the FDA has also warned that SGLT2 inhibitors can cause kidney injuries, bone fractures, breast and bladder cancer and pancreatitis among...Continue Reading
Doctors find certain diabetes drugs can increase the chance for potentially fatal acidic blood condition. In a June 8, 2017 correspondence to the New England Journal of Medicine, doctors associated with Harvard Medical School wrote that SGLT2 inhibitors, a class of type 2 diabetes drugs that includes Invokana and Invokamet, can double the risk of diabetic ketoacidosis when compared to DPP4 inhibitors, a different kind of diabetes drug. The researchers identified patients who had recently started treatment of their diabetes...Continue Reading
Trials find the drug doubles the risk of leg and foot amputation In a recent communication, the U.S. Food and Drug Administration (FDA) warned patients that taking the type 2 diabetes drug canagliflozin (Invokana, Invokamet, Invokamet XR) can cause an increased risk of leg and foot amputations. The FDA says patients taking Invokana and similar drugs should notify their doctor as soon as possible if they find new pain and tenderness in their feet and legs. Invokana and Invokamet are...Continue Reading
Scientists at Yale find approval not a guarantor of drug safety Researchers at the Yale School of Medicine have published a 2017 report showing that of 222 drugs the U.S. Food and Drug Administration (FDA) approved between 2001 and 2010, 71 were affected by safety events after they had already been sold to patients. Dr. Joseph Ross and his colleagues studied the FDA’s approval process for new drugs and found that the median time from the FDA’s approval of the...Continue Reading
Over 18,000 patients accuse Johnson & Johnson and Bayer of failing to inform doctors about the dangers of the blood-thinning drug. On April 24th, a bellwether trial began in the lawsuit against the stroke drug, Xarelto, manufactured by Johnson & Johnson and Bayer. The plaintiffs accuse the pharmaceutical companies of failing to provide sufficient information about the risks involved in taking Xarelto, including what the plaintiffs claim is a high chance for severe bleeding events. The Chicago Tribune reports that...Continue Reading
Speak with a Lawyer
Contact an attorney today for a free and confidential legal consultation.